LEADER 03673nam  22004455  450 
001 9910254477503321
005 20251116172411.0
010   $a3-319-53560-9
024 7 $a10.1007/978-3-319-53560-9
035   $a(CKB)3710000001175884
035   $a(DE-He213)978-3-319-53560-9
035   $a(MiAaPQ)EBC4839070
035   $a(PPN)20051332X
035   $a(EXLCZ)993710000001175884
100   $a20170410d2017      u|         0
101 0 $aeng
135   $aurnn#008mamaa
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aAsbestos and mesothelioma /$fedited by Joseph R. Testa
205   $a1st ed. 2017.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2017.
215   $a1 online resource (VIII, 407 p. 65 illus., 43 illus. in color.)
225 1 $aCurrent Cancer Research,$x2199-2584
311 08$a3-319-53558-7 
320   $aIncludes bibliographical references.
327   $a1. Malignant Mesothelioma ? An Asbestos Legacy -- 2. Asbestos and Fibrous Erionite -- 3. Epidemiology of Mesothelioma -- 4. Malignant Pleural Mesothelioma: History, Controversy and Future of a Man-Made Epidemic  -- 5. Communities at High Risk in the Third Wave of Mesothelioma -- 6. Mesothelioma Pathology -- 7. Asbestos-Induced Inflammation in Malignant Mesothelioma and Other Lung Diseases -- 8. Germline and Somatic Mutations in Human Mesothelioma and Lessons from Asbestos-Exposed Genetically Engineered Mouse Models -- 9. Gene Signature of Malignant Pleural Mesothelioma -- 10. Cell Signaling and Epigenetic Mechanisms in Mesothelioma -- 11. 3D Models of Mesothelioma in the Study of Mechanisms of Cell Survival -- 12. Biomarkers of Response to Asbestos Exposure -- 13. Surgery Approaches in Mesothelioma -- 14. Radiotherapy and Photodynamic Therapy for Malignant Pleural Mesothelioma -- 15. Standard Chemotherapy Options and Clinical Trials of Novel Agents for Mesothelioma -- 16. Immunotherapeutic Approaches to Mesothelioma -- 17. Challenges Facing Mesothelioma Patients and Their Families: Medical/Legal Intersections -- 18. The Patient?s Experience of Malignant Mesothelioma.
330   $aThis volume is comprised of a multidisciplinary assessment of the interplay between asbestos and cancer as well as new research about the biology and treatment of malignant mesothelioma. Chapters on the various types of asbestos and other mineral fibers, epidemiology, history and future of asbestos-related diseases are included. Other reviews present new information about the role of asbestos-related inflammation and genetic factors, including the role of inherited mutations of BAP1, in mesothelioma causation, as well as recent research about gene signatures, cell signaling, and epigenetic mechanisms in asbestos-related diseases. Other chapters provide updates of novel disease biomarkers and prevention, mechanistic lesson from genetically engineered mouse and 3-D models of mesothelioma tumorigenesis and therapeutic resistance. Also included are up-to-date reviews of surgical, molecularly targeted chemotherapeutic, and immunotherapeutic approaches for mesothelioma as well as an overview of legal issues.
410  0$aCurrent Cancer Research,$x2199-2584
606   $aCancer$xResearch
606   $aCancer Research$3https://scigraph.springernature.com/ontologies/product-market-codes/B11001
615  0$aCancer$xResearch.
615 14$aCancer Research.
676   $a614.5999
702   $aTesta$b Joseph R.$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910254477503321
996   $aAsbestos and Mesothelioma$91551278
997   $aUNINA